Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|May 5, 2011
OpenClinica to Unveil New Software Release at Global Conference
Advertisement
Culminating 18 months of research, development and testing,
Ben Baumann, OpenClinica’s Director of Business Development, says the conference will feature a number of demonstration sessions designed to give attendees a live, hands-on experience with the new technology.
OpenClinica facilitates the development of new medical treatments by lowering the cost of clinical trials while raising the standards for efficiency and transparency in clinical research.
The OpenClinica Global Conference brings together users, developers, and other stakeholders from the OpenClinica community to share knowledge and best practices. The event features lectures, case studies, tutorials, panel discussions, posters, and technical demonstrations. Participants in the event represent numerous countries including China, Brazil, Germany, India, Denmark, Taiwan, Austria, Switzerland, Argentina, and the United Kingdom. Participants represent biopharmaceutical companies, device companies, contract research organizations, academic centers, and government agencies.
Kenneth A. Getz, Chairman of the Center for Information & Study on Clinical Research Participation
“The sustainability of drug development desperately depends on new models of innovation,” said Mr. Getz. “Innovative open source projects like OpenClinica hold tremendous promise for addressing this need,” Getz said.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Where AI Governance in Clinical Development Falls Short
5